Tarek Dbouk, MD
Gynecology · Lorain, OHNPI 1215114913
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Coloplast at 27.9% of the total.
Across 166 payments — averaging $42.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- Intuitive Surgical$2K
- Medtronic$736
- AbbVie$661
- Boston Scientific$478
- Astellas Pharma US Inc$316
- plus $1K from 26 others
What the payments were for
- Travel & lodging$1,71624%
- Food & beverage$3,86954%
- Education$1,53322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 18 | $1,989 |
| Intuitive Surgical | 1 | $1,500 |
| Medtronic(2 entities) | 34 | $736 |
| AbbVie(2 entities) | 28 | $661 |
| Boston Scientific | 3 | $478 |
| Astellas Pharma US Inc | 17 | $316 |
| Meditrina | 6 | $221 |
| Axonics, Inc. | 10 | $174 |
| Gynesonics, Inc. | 4 | $156 |
| Therapeuticsmd, Inc. | 8 | $131 |
| Acessa Health Inc. | 1 | $114 |
| Myovant Sciences Inc. | 6 | $88 |
| Organon | 1 | $81 |
| Pfizer | 3 | $69 |
| Hologic Sales And Service, LLC | 3 | $53 |
| Minerva Surgical, Inc | 2 | $37 |
| Roche Diagnostics Corporation | 2 | $35 |
| Mylan Pharmaceuticals Inc. | 2 | $31 |
| Lupin Inc. | 2 | $30 |
| Coopersurgical, Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $15 |
| Gilead | 1 | $15 |
| Scynexis, Inc. | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Duchesnay USA Incorporated | 1 | $13 |
| Electromed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$1,594
- DAVINCI XI$1,500
- SOLYX$430
- INTERSTIM$356
- ACESSA PROVU SYSTEM$114
How this compares
$7,118 in reported general payments places this provider in the 85th percentile of 77 gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 180 | $98,806 |
| GemtesaVibegron | 41 | $20,559 |
| Mirabegron ErMirabegron | 21 | $11,529 |
| PremarinEstrogens, Conjugated | 18 | $8,212 |
| Trospium Chloride ErTrospium Chloride | 20 | $4,628 |
| Estradiol | 49 | $2,818 |
| Darifenacin ErDarifenacin Hydrobromide | 20 | $2,658 |
| NitrofurantoinNitrofurantoin Macrocrystal | 84 | $2,099 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $1,663 |
| Solifenacin Succinate | 50 | $1,437 |
| Clindamycin Phosphate | 23 | $1,297 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 112 | $1,255 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $1,092 |
| Trimethoprim | 14 | $958 |
| Ibuprofen | 69 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $316 | $98,806180 claims |
| PfizerPremarin | $69 | $8,21218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 gynecology providers in Ohio.
Other gynecology in Lorain
- Patricia YostLorain$743
- Derek VanamerongenCincinnati$316K
- Megan BillowCleveland$83K
- Rachel PopeCleveland$49K
- Rosanne Marie KhoCleveland$19K
- Joseph FranzeseCincinnati$18K
- Susan Clark-FrantzNorton$10K
- Amber Bondurant SullivanGahanna$8K
- Marianna VardakaCincinnati$8K
- Amol AroraWesterville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.